Provider - Focused Strategies: Prescriber - DEA Scheduling

DEA.   21 CFR Part 1308                   Docket No. DEA-333         DEA Notification

Schedules of Controlled Substances: Placement of Carisoprodol Into Schedule IV: Final rule.

DEA places carisoprodol into Schedule IV of the Controlled Substances Act (CSA).  Effective Date: January 11, 2012.

Bernhardt MB, Taylor RS, Hagan JL, et al. Evaluation of opioid prescribing after rescheduling of hydrocodone-containing products. Am J Health Syst Pharm. 2017;74(24):2046-53.  Abstract

Chumpitazi CE, Rees CA, Camp EA, Bernhardt MB. Decreased opioid prescribing in a pediatric emergency department after the rescheduling of hydrocodone. J Emerg Med. 2017;52(4):547-53.  Abstract

Fernandez J, Thornton JD, Rege S, et al. Prescribers’ perceptions on the impact of hydrocodone rescheduling on geriatric pain management: a qualitative study. J Opioid Manag. 2018;14(5):317-26.  Abstract

Fleming ML, Driver L, Sansgiry SS, et al. Drug Enforcement Administration rescheduling of hydrocodone combination products is associated with changes in physician pain management prescribing preferences. Pain Palliat Care Pharmacother. 2019;33(1-2):22-31.  Abstract

Fleming ML, Driver L, Sansgiry SS, et al. Physicians’ intention to prescribe hydrocodone combination products after rescheduling: a theory of reasoned action approach. Res Social Adm Pharm. 2017;13(3):503-12.  Abstract

Gibson DC, Chou L-N, Raji MA, et al. Opioid prescribing trends in women following mastectomy or breast-conserving surgery before and after the 2014 federal reclassification of hydrocodone. Oncologist. 2020;25(4):281-9.  Article

Habbouche J, Lee J, Steiger R, et al. Association of hydrocodone schedule change with opioid prescriptions following surgery. JAMA Surg. 2018;153(12):1111-1119.  Article

Haynes A, Kleinschmidt K, Forrester MB, Young A. Trends in analgesic exposures reported to Texas Poison Centers Following increased regulation of hydrocodone. Clin Toxicol (Phila). 2016;54(5):434-40.  Abstract

Liaw V, Kuo Y-F, Raji MA, Baillargeon J. Opioid prescribing among adults with disabilities in the United States after the 2014 federal hydrocodone rescheduling regulation. Public Health Rep. 2020;135(1):114-23.  Abstract

Neuman MD, Hennessy S, Small DS, et al. Drug Enforcement Agency 2014 hydrocodone rescheduling rule and opioid dispensing after surgery. Anesthesiology. 2020;132(5):1151-64.  Abstract

Northrup TF, Carroll K, Suchting R, et al. The impact of increased hydrocodone regulation on opioid prescribing in an urban safety-net health care system. J Am Board Fam Med. 2019;32(3):362-74.  Article

Oehler EC, Day RL, Robinson DB, Brown LH. Has the rescheduling of hydrocodone changed ED prescribing practices? J Emerg Med. 2016;34(12):2388-91.  Abstract

Raji MA, Kuo Y-F, Adhikari D, et al. Decline in opioid prescribing after federal rescheduling of hydrocodone products. Pharmacoepidemiol Drug Saf. 2018;27(5):513-9.  Article

Reeves RR, Burke R, Kose S. Carisoprodol: update on abuse potential and legal status. Southern Med J. 2012;105(11):619-23.  Abstract

Seago S, Hayek A, Pruszynski J, Newman MG. Change in prescription habits after federal rescheduling of hydrocodone combination products. Proc (Bayl Univ Med Cent). 2016;29(3):268-70.  Article

Spiller HA, Scaglione JM, Aleguas A, et al. Effect of scheduling tramadol as a controlled substance on poison center exposures to tramadol. Ann Pharmacother. 2010;44:1016-21.  Abstract

Sun C, Hollenbach KA, Cantrell FL. Trends in carisoprodol abuse and misuse after regulatory scheduling: a retrospective review of California poison control calls from 2008 to 2015. J Clin Toxicol. 2018;56: 653-5.  Abstract

Tran S, Lavitas P, Stevens K, et al. The effect of a federal controlled substance act schedule change on hydrocodone combination products claims in a Medicaid population. J Manag Care Spec Pharm. 2017;23(5):532-9.  Abstract